Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Joseph W KimRana R McKayMarc R RadkeShilin ZhaoMary-Ellen TaplinNancy B DavisPaul MonkLeonard J ApplemanPrimo N LaraUlka N VaishampayanJingsong ZhangAsit K PaulGlenn BubleyEliezer Van AllenSerhan ÜnlüYing HuangMassimo LodaGeoffrey I ShapiroPeter M GlazerPatricia M LoRussoSusan Percy IvyYu ShyrElizabeth M SwisherDaniel P PetrylakPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
-mutated subgroups treated with olaparib with or without cediranib were associated with a numerically longer median rPFS.